Impact of BPC-157 on Recovery Following Rotator Cuff Repair Surgery
Impact of BPC-157 on Recovery From Rotator Cuff Repair Surgery
This study is a randomized, double-blind, placebo-controlled pilot trial investigating the effects of BPC-157 on tendon healing and functional recovery following arthroscopic rotator cuff repair (aRCR). BPC-157 is a synthetic peptide that has demonstrated promising regenerative and anti-inflammatory effects in preclinical animal models of musculoskeletal injury, but it has not yet been studied in formal human clinical trials.
Twenty patients undergoing aRCR will be enrolled and randomly assigned to receive either BPC-157 or a saline placebo. Participants will self-administer subcutaneous injections daily for 90 days following surgery. All other aspects of care will follow the standard postoperative rehabilitation protocol.
The study will assess tendon healing using postoperative MRI, patient-reported outcome measures (PROMs), range of motion (ROM), and muscle strength via handheld dynamometry. Blood samples will also be collected to evaluate biomarkers associated with collagen turnover and inflammation.
The goal of this pilot study is to evaluate the safety, feasibility, and preliminary efficacy of BPC-157 in promoting tendon healing and improving functional outcomes after rotator cuff repair. Results will inform the design of a future larger-scale clinical trial.
Studie Overzicht
Toestand
Toestand
Conditie
Conditie
Interventie / Behandeling
Interventie / Behandeling
Studietype
Studietype
Inschrijving (Geschat)
Inschrijving
Fase
Fase
- Fase 1
Contacten en locaties
Studie Locaties
-
-
Arkansas
-
Little Rock, Arkansas, Verenigde Staten, 72205
- University of Arkansas for Medical Sciences Medical Center
-
Contact:
- Shiloah Kviatkovsky
- Telefoonnummer: 619-677-0792
- E-mail: skviatkovsky@uams.edu
-
Hoofdonderzoeker:
- Shiloah Kviatkovsky, P.h.D.
-
Onderonderzoeker:
- Ryan Hill, M.D.
-
-
Deelname Criteria
Geschiktheidscriteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Volwassen
- Oudere volwassene
Accepteert gezonde vrijwilligers
Beschrijving
Inclusion Criteria:
- Males and Females, 18 years old or older
- Body mass index of 20.0 to 34.9 kg/m2
- Pre-operative MRI demonstrating a full thickness tear of the posterosuperior rotator cuff less than 2.5 cm in anteroposterior dimension
- Scheduled for an aRCR at UAMS with Dr. Ryan Hill, Dr. Paul Inclan, or Dr. Justin Rabinowitz
- COVID-19 negative and/or asymptomatic
Exclusion Criteria:
- Previous RCR
- Pregnant or breastfeeding status
- Current drug and alcohol abuse · History of platelet-rich plasma injection, other platelet-based product or biologic injection in the past 12 months in the ipsilateral shoulder
- Lack of decisional capacity
- Having undergone hormone replacement therapy in the last 12 months
- Having undergone testosterone replacement therapy in the last 12 months
- Active diagnosis of blood borne infectious disease
- Diabetic
- Documented history or diagnosis of autoimmune disease
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Verviervoudigen
Aantal wapens
Wapens en interventies
Deelnemersgroep / ArmDeelnemersgroep / Arm |
Interventie / BehandelingInterventie / Behandeling |
|---|---|
|
Experimenteel: BPC-157 Group
Participants in this arm will receive BPC-157.
BPC-157 will be self-administered via subcutaneous injection once daily for 90 days following arthroscopic rotator cuff repair.
All participants will follow the standard postoperative rehabilitation protocol in addition to the study intervention.
|
BPC-157 is a synthetic pentadecapeptide derived from human gastric juice.
It has demonstrated pro-angiogenic, cytoprotective, and tissue-regenerative effects in multiple preclinical models of musculoskeletal injury, including tendon and ligament healing.
Although widely discussed in experimental and anecdotal contexts, BPC-157 has not undergone formal human clinical trials and remains an investigational compound not approved by the FDA.
This study is designed to explore its potential role in promoting tendon regeneration and functional recovery in a postoperative orthopaedic setting.
|
|
Sham-vergelijker: Sham
Participants in this arm will receive normal saline.
Normal saline will be self-administered via subcutaneous injection once daily for 90 days following arthroscopic rotator cuff repair.
All participants will follow the standard postoperative rehabilitation protocol in addition to the study intervention.
|
Participants in this group will not receive any active treatment or placebo injections.
This sham group serves as a no-treatment control to evaluate the natural course of postoperative recovery following arthroscopic rotator cuff repair without investigational intervention.
Participants will continue to receive standard postoperative care and rehabilitation in accordance with institutional protocols.
This group is included to help differentiate the effects of BPC-157 from both placebo and routine recovery.
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Shoulder Strength
Tijdsspanne: Baseline, 12 weeks, and 5 months post operatively
|
Isometric shoulder abduction strength will be assessed using a handheld dynamometer.
Strength measurements will focus on shoulder abduction and external rotation at 0° abduction.
Three trials will be recorded, and the average peak force will be used as the outcome value.
Testing will be performed by a blinded evaluator using a standardized protocol.
|
Baseline, 12 weeks, and 5 months post operatively
|
Medewerkers en onderzoekers
Sponsor
Sponsor
Studie record data
Bestudeer belangrijke data
Studie start (Geschat)
Studie start
Primaire voltooiing (Geschat)
Primaire voltooiing
Studie voltooiing (Geschat)
Studie voltooiing
Studieregistratiedata
Eerst ingediend
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Eerst geplaatst
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update geplaatst
Laatste update ingediend die voldeed aan QC-criteria
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
Andere studie-ID-nummers
- 298969
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .